YGION Biomedical
Latest round
- Series A
Last raised
- May 2024
Total raised
- $16M
Investors
- 1
About YGION Biomedical
a. YGION Biomedical operates as a biotechnology company that focuses on developing individualized neoantigen-based cancer vaccines. The company provides cancer treatment by developing targeted therapies that harness the patient’s immune system to fight tumors. approach involves a proprietary immune-modulating carrier, CARGONAUT, which delivers neoepitope peptides to antigen-presenting cells, triggering a precise and potent immune response. Using advanced tumor genomics and bioinformatics, YGION's YGNITE platform creates personalized plug-and-play cancer vaccines tailored to each patient's tumor.
Who invested in YGION Biomedical
1 investor across 1 round
See all investors in YGION Biomedical
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
May 21, 2024
Amount
$16M
Investors
Questions about YGION Biomedical
Who invested in YGION Biomedical?
YGION Biomedical has 1 investor on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has YGION Biomedical raised?
YGION Biomedical has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did YGION Biomedical last raise money?
YGION Biomedical's most recent round on record is a Series A, in May 2024.
What does YGION Biomedical do?
YGION Biomedical is a biotechnology company.
Where is YGION Biomedical headquartered?
YGION Biomedical is headquartered in Vienna, Austria.
Which VCs invest in companies like YGION Biomedical?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Highland Europe back biotechnology companies at YGION Biomedical's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like YGION Biomedical? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.